User profiles for Celine I. Mandara
 | Celine MandaraMD, MSc, PhD Verified email at nimr.or.tz Cited by 568 |
[HTML][HTML] Potential opportunities and challenges of deploying next generation sequencing and CRISPR-Cas systems to support diagnostics and surveillance towards …
Recent developments in molecular biology and genomics have revolutionized biology and
medicine mainly in the developed world. The application of next generation sequencing (NGS…
medicine mainly in the developed world. The application of next generation sequencing (NGS…
Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions among patients enrolled at 100 health facilities throughout Tanzania: February to July 2021
…, C Herman, A Barakoti, RA Madebe, CI Mandara… - Scientific Reports, 2024 - nature.com
Plasmodium falciparum with the histidine rich protein 2 gene (pfhrp2) deleted from its genome
can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World …
can escape diagnosis by HRP2-based rapid diagnostic tests (HRP2-RDTs). The World …
[HTML][HTML] Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
We describe the MalariaGEN Pf7 data resource, the seventh release of Plasmodium falciparum
genome variation data from the MalariaGEN network. It comprises over 20,000 samples …
genome variation data from the MalariaGEN network. It comprises over 20,000 samples …
Efficacy and safety of artemisinin-based combination therapy, and molecular markers for artemisinin and piperaquine resistance in Mainland Tanzania
…, MK Mahende, DS Ishengoma, CI Mandara… - Malaria journal, 2018 - Springer
Background Artemisinin-based combination therapy (ACT) is the first-line anti-malarial
treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania. …
treatment of uncomplicated malaria in most malaria endemic countries, including Tanzania. …
Malaria species positivity rates among symptomatic individuals across regions of differing transmission intensities in Mainland Tanzania
…, D Pereus, DJ Giesbrecht, CI Mandara… - The Journal of …, 2024 - academic.oup.com
Background Recent data indicate that non-Plasmodium falciparum species may be more
prevalent than thought in sub-Saharan Africa. Although Plasmodium malariae, Plasmodium …
prevalent than thought in sub-Saharan Africa. Although Plasmodium malariae, Plasmodium …
Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of …
DS Ishengoma, CI Mandara, F Francis, E Talundzic… - Malaria journal, 2019 - Springer
Background The World Health Organization recommends regular therapeutic efficacy studies
(TES) to monitor the performance of first and second-line anti-malarials. In 2016, efficacy …
(TES) to monitor the performance of first and second-line anti-malarials. In 2016, efficacy …
Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes
High‐throughput Plasmodium genomic data is increasingly useful in assessing prevalence
of clinically important mutations and malaria transmission patterns. Understanding parasite …
of clinically important mutations and malaria transmission patterns. Understanding parasite …
Community-based surveys for Plasmodium falciparum pfhrp2 and pfhrp3 gene deletions in selected regions of mainland Tanzania
C Bakari, S Jones, G Subramaniam, CI Mandara… - Malaria Journal, 2020 - Springer
Background Histidine-rich protein 2 (HRP2)-based malaria rapid diagnostic tests (RDTs)
are effective and widely used for the detection of wild-type Plasmodium falciparum infections. …
are effective and widely used for the detection of wild-type Plasmodium falciparum infections. …
High efficacy of artemether–lumefantrine and dihydroartemisinin–piperaquine for the treatment of uncomplicated falciparum malaria in Muheza and Kigoma Districts …
CI Mandara, RA Kavishe, S Gesase, J Mghamba… - Malaria journal, 2018 - Springer
Background Artemether–lumefantrine (AL) is the recommended first-line artemisinin-based
combination therapy (ACT) for the treatment of uncomplicated falciparum malaria in most of …
combination therapy (ACT) for the treatment of uncomplicated falciparum malaria in most of …
[HTML][HTML] Capacity development through the US President's malaria initiative–supported antimalarial resistance monitoring in Africa network
…, NW Lucchi, Z Zhou, CI Mandara… - Emerging infectious …, 2017 - ncbi.nlm.nih.gov
Antimalarial drug resistance is an evolving global health security threat to malaria control.
Early detection of Plasmodium falciparum resistance through therapeutic efficacy studies and …
Early detection of Plasmodium falciparum resistance through therapeutic efficacy studies and …